Compounded semaglutide and tirzepatide became common while the brand-name drugs were in shortage, and for many people without coverage they were the only version they could afford. The shortages are over and the rules have tightened, but the cost problem that sent people to compounders is still there, and that tension is what keeps the argument going.
How the debate started
While the FDA listed brand-name semaglutide and tirzepatide as in shortage, federal rules let compounding pharmacies make copies of them to meet demand the manufacturers couldn't fill. For many patients, especially those without insurance coverage or facing high out-of-pocket costs, a compounded version was how they got treated at all.
The FDA declared the tirzepatide shortage resolved on December 19, 2024, and the semaglutide shortage resolved on February 21, 2025. It then gave compounders a wind-down period: state-licensed 503A pharmacies had until February 18, 2025 (tirzepatide) and April 22, 2025 (semaglutide) to stop making copies, and 503B outsourcing facilities had until March 19, 2025 and May 22, 2025. After that, the law restricts both kinds of compounder from making drugs that are "essentially a copy" of an FDA-approved drug. For an outsourcing facility, that means its product can't be identical or nearly identical to an approved drug unless the approved drug is on the FDA's shortage list. For a 503A pharmacy, the limit is on compounding copies "regularly or in inordinate amounts", and the FDA doesn't treat a compounded drug as a copy if a prescriber determines and documents that a change makes a significant difference for an identified patient (FDA (external link)). That exception is why compounded versions are still prescribed, and much of the argument now turns on how it's used. Outsourcing facilities could also get back into the market if the FDA put these drugs on its 503B bulks list. On April 30, 2026 the FDA announced a proposal not to (published in the Federal Register on May 1), and after one extension the public comment period closed on July 30, 2026 (Federal Register (external link)). As of September 2026, no final decision had been published (see our guide on the FDA's 503B bulks-list proposal).
The access argument
The case for compounding starts with cost. In a KFF poll published November 14, 2025, 56% of adults taking a GLP-1 said the drugs were difficult to afford, and one in four said "very difficult" (KFF (external link)). The compounding industry's trade group, the Alliance for Pharmacy Compounding, says outsourcing facilities "played an important role in helping meet patient needs" during the shortages and wants any final policy to reflect "the practical realities of patient care" (APC (external link)). Advocates for compounding argue that if it's restricted and affordability isn't fixed, people who can't pay brand-name prices or don't have enough coverage lose treatment. Those are largely the same groups described in our guide on access disparities.
The safety argument
The FDA points to problems specific to compounded GLP-1s: inconsistent dosing, product purity, unapproved salt forms, and a grey market of online sellers that can look, to a patient, just like a licensed compounder. Novo Nordisk, which makes Ozempic and Wegovy, says compounded samples "may contain lower-than-indicated strengths or no semaglutide at all" and often have new or higher levels of impurities (Novo Nordisk (external link)). The FDA says it has received reports of adverse events, some requiring hospitalization, that may be linked to dosing errors with compounded injectable semaglutide. As of May 31, 2026, it had 990 adverse event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. Those numbers are likely an undercount, because federal law doesn't require state-licensed pharmacies that aren't outsourcing facilities to report adverse events to the FDA.
Where the two sides can meet
Cost does block access for many patients, and quality does vary among compounded products, most of all from illegitimate or unlicensed sources. The more useful advocacy positions are specific. Push for enforcement against grey-market sellers and for clear quality standards for legitimate compounders. Then push on the cause: better insurance coverage and lower list prices mean fewer people need compounding as a cost workaround at all.
How to engage with this as a patient or advocate
If you use or have used a compounded GLP-1, find out what kind of source it came from. A state-licensed 503A compounding pharmacy is overseen mainly by your state board of pharmacy and is not bound by federal current good manufacturing practice (CGMP) rules. An FDA-registered 503B outsourcing facility must meet CGMP and is inspected by the FDA. An unlicensed online seller has neither kind of oversight. For advocacy, affordability and supply are the underlying causes, so they're the most useful place to aim pressure.
This article is general education, not medical, legal, or pharmacy advice. Compounding rules and FDA policy change over time. Check current FDA guidance and your state board of pharmacy, and talk with your prescriber before starting or switching a medication.